Objective: To analyze the rationality of antimicrobial (AM) and respiratory (RP) fi xed dose combinations (FDCs) available in Indian market. Materials and Methods: Antimicrobial and RP FDCs enlisted in Indian Drug Review 2010 and 2013 respectively were analyzed by a pretested validated 8 point criteria tool. Each FDC was assessed for number of active pharmacological ingredients, approval by regulatory authority, listing in World Health Organization (WHO) essential medicine list (EML) or National List of Essential Medicine. While effi cacy, safety, pharmacokinetic and pharmacodynamic interactions and advantages of each FDC were analyzed by evidence based literature search. Each criterion was scored one for positive and minus one for negative or unfavorable observation. The total score for the tool was 12 and score ≥7 was considered rational. Results: Of 209 FDCs, 108 were AMs and 101 were RPs. The mean rationality score was 5.41 ± 1.63 (95% CI, 2.15-8.67). Majority of FDCs were irrational (174) while 35 were rational, and only 12 of these were listed in WHO EML 2013. Out of 108 AM FDCs, 21 (19%) were rational while 87 (81%) were irrational. Out of 101 RP FDCs, 14 (14%) were rational while 87 (86%) were irrational and 24 (24%) with unfavorable pharmacodynamic interactions. Majority of the rational AM FDCs were antiretroviral (6) agents while RP FDCs were indicated for chronic obstructive pulmonary diseases. While majority of irrational FDCs were AM plus steroids, β 2 agonists plus antihistaminics/expectorants/anticholinergics/mast cell stabilizers/leukotriene receptor antagonists. Conclusion: Rationality assessment of AM and RP FDCs reveals that a substantial number of these FDCs in Indian market are irrational. This calls for a close scrutiny of marketed FDCs and educating prescribers to use them with great care and caution. This also indicates a serious review of the regulatory framework for drug manufacturing and marketing.
INTRODUCTION
Fixed dose combination (FDC) is defi ned as "A combination of two or more active ingredients in a single dosage form in a fi xed ratio of doses." FDC products are acceptable when the dosage of each ingredient meets the requirement of a defi ned population, and the combination has a proven advantage over single compounds administered separately in therapeutic effect, safety and compliance.
[1] World Health Organization (WHO) essential medicine list (EML) 2013 includes 24 FDCs and most of them belong to antiretroviral, antitubercular and antimalarial class. [2] Earlier, The Drug and Cosmetic Act (1940) stated "no additional or human data is required and approval to market the product was granted for FDC with an acceptable rationale." This resulted in mushrooming of FDCs in India, accounting for approximately 44% of domestic pharmaceutical market. [3] However, an Amendment in 2005 clearly stated FDCs as new drugs and must comply the Schedule Y for marketing approval. With this, FDCs have been categorized into two types for regulatory approval. One, any one of the ingredient is new and proposed to be used for the 1 st time is considered a new drug. While FDC in which ingredients are individually approved and marketed for certain claims and are proposed to be combined for 1 st time in a fi xed ratio or if the ratio of the ingredients in an already marketed combination is proposed to be changed for a particular claim is considered as second category. Thus, the marketing approval of FDC requires to submit all necessary pharmacological, toxicological and clinical data of individual drug along with the rationale of the combination. Central Drug Standard Control Organization in August 2010 had laid down guidelines for approving the FDCs emphasizing the rationale of combining drugs in a specifi c ratio. [4] However, there is no available validated tool to assess the rationality. Thus, the present study was aimed to design a tool to assess the rationality of antimicrobial (AM) and respiratory (RP) FDCs available in Indian market.
MATERIALS AND METHODS
A cross-sectional, observational study was conducted at the Department of Pharmacology, B. J. Medical College, Ahmedabad, Gujarat. The data were collected from an annual Drug Compendium entitled "Indian Drug Review" (IDR) 2010 and 2013 that enlist most of the medicines commercially available in India during a particular year.
Antimicrobial and RP FDCs enlisted in IDR 2010, and 2013 respectively were assessed for rationality. A tool was designed using WHO guidelines for registration of fi xed dose combination medicinal products.
[1] The tool consisted of eight point criteria [ Figure 1 ]. The criteria in the tool included active pharmacological ingredient (API) with strength, its effi cacy, safety, approval by regulatory authority, listing in WHO EML or National List of Essential Medicines of (NLEM). The evidence for effi cacy and safety of the individual API and their combination was searched using standard textbooks, reference books of pharmacology and medicine. In addition, authentic web sources like PubMed data base, Google scholar and Cochrane data base were also used. Pharmacokinetic and pharmacodynamic interactions were checked using Medscape drug interaction checker. Advantages of FDC over individual API in the form of dose reduction, less adverse drug reactions and reduced frequency of administration were assessed by above mentioned evidence based literature search.
As per subject experts opinion form industry and academia each criterion was scored plus one (+1) for positive and minus one (−1) for negative or unfavorable observation. The total score ranged from 1 to 12 and score ≥7 was considered rational. Further the tool was validated by assessment of FDCs already approved by WHO EML 2013 whereby the minimum score obtained of these was seven. The data was entered in Microsoft excel sheet and analyzed using appropriate statistical tests.
RESULTS
Out of 209 FDCs, 108 belonged to AM group and 101 to RP group. The mean rationality score of AM FDCs was 4.91 ± 1.72 while that of RP FDCs was 5.92 ± 1.55. Majority of AM FDCs contained two APIs (90) while majority of RP FDCs contained 3 or >3 active ingredients [ Table 1 and Figure 2 ]. The rationality score for 12 AM FDCs listed in WHO EML was ≥7 [ Table 2 ]. In 
DISCUSSION
The results of this study show that a large number of AM and RP FDCs are available in Indian market. Unfortunately, their rationality assessment showed that majority had a score <7 indicating towards irrationality.
The rational AM FDCs were antiretroviral, antitubercular and antimalarial class of drugs with proven efficacy, safety, pharmacokinetic and pharmacodynamic advantages. [5, 6] While 81% of AM FDCs were irrational, with no justifi cation of combining the ingredients. Our results are in conformity with the observation made by Rayasam et al. in 2013 to study prescribing pattern of FDCs among practitioners in central India. [7] The most pressing concern with irrational FDCs was illogical combination of antibacterial with corticosteroid which decreases the immunity and increases the susceptibility to infections. Moreover, combination of cephalosporin with beta lactamase inhibitor is also not justifi ed as beta lactamse inhibitors prevent destruction of beta lactam ring in penicillin group of antibiotics and thus widens the antibacterial spectrum of latter. However, these are not effective against the extended spectrum cephalosporins such as ceftazidime, ceftriaxone, cefotaxime. [8] A large number of AM FDCs were fashionable combination of antibacterial with antiamoebic and/or antifungal agents. Amoebic and bacterial infection rarely coexist and such combination not only encourage resistance, but also expose patients to unnecessary risk of adverse drug reactions. [9] Such FDCs have not been recommended in any standard books, but continue to be available in Indian market. Availability of such products reduces the attempt for a precise diagnosis and only adds to the cost of therapy. It is a wellknown fact that lactobacilli as a single agent is used for diarrhea. However, none of the combination of antibacterial plus lactobacilli had adequate dose (5-10 billion) required to decrease antibacterial induced diarrhea. In addition, many FDCs were combined with serratiopeptidase, an enzyme claimed to promote rapid resolution of infl ammation. To our surprise, we could not fi nd any evidence in published literature such as standard books or peer reviewed scientifi c journals supporting this claim.
On the other hand, no RP FDC has been listed in WHO EML. Majority of RP FDCs (86%) in our study were irrational, many of them targeting cough and the common cold, a self-limiting condition that does not require medicine to cure or prevent it. [10] Similar observations have been reported by Roy et al. [11] and Desai et al. [10] Interestingly, our tool found 14 RP FDCs rational with respect to effi cacy, safety, and compliance. For example, the combination of long acting β 2 agonist with corticosteroid is rational because corticosteroids increase the expression of β 2 receptors by increasing gene transcription and reduces the adverse effects of β2 agonist, whereas β 2 -agonists potentiates the local anti-inflammatory actions of corticosteroids by increasing nuclear localization of glucocorticoid receptors and additive suppression of infl ammatory mediator release. [12] Further, combination of methylxanthines plus β 2 -agonists potentiates the therapeutic effect with fewer side effects as compared to β 2 -agonists alone. [13, 14] Literature states that combination therapy with β 2 -agonists and anticholinergics is also effective with improvement of dynamic lung function and good safety profi le in patients of chronic obstructive pulmonary diseases. [15] FDCs of montelukast with antihistaminics were also found to be rational due to its enhanced and complementary pharmacological and clinical effects leading to a reduction in the day and night time symptoms effectively in patients of allergic rhinitis. [16] A great discrepancy was observed in the total number of AM and RP FDCs available in Indian market as compared to WHO EML and NLEM. The WHO EML 2013 includes a total of 18 AM FDCs out of total 120 AMs with nil from RP system. Thus, it is almost 11 times the numbers of FDCs to treat infectious and RP diseases in India.
Although there has been no defi ned rule for the permissible maximum number of constituents in the FDCs, any FDC containing >3 ingredients should be looked at watchfully. Majority of AM FDCs had two ingredients, albeit, majority of RM FDCs had 3 or >3 ingredients. US FDA states that there is no rationale of combining >3 ingredients. [17] A commercial and commonly used annual drug compendium among the prescribers was used for data collection and source of information for formulations available in Indian market. A possibility of lack of complete information cannot be ruled out. Nevertheless, the compendium still refl ects the actual scenario of marketed drug product of the country.
Thus, it can be concluded that a large number of AM and RP irrational FDCs to treat clinical conditions are available in Indian market. It is indeed very unfortunate and unethical to expose the innocent patients to medicines with unproven effi cacy and safety. This calls for a close scrutiny of marketed FDCs and educating prescribers to use them with great care and caution. This also indicates a serious review of the regulatory framework for drug manufacturing and marketing.
